Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17233832 | 1.00 | CYP17A1 (0.50) | CYP17A1CYP19A1F7F3SARM1 | |
| SCHEMBL17233924 | 1.00 | CYP17A1 (0.50) | CYP17A1CYP19A1F7F3SARM1 | |
| SCHEMBL30159419 | 1.00 | CYP17A1 (0.50) | CYP17A1CYP19A1F7F3SARM1 | |
| Hydrochloric Acid SCHEMBL5349524 | 0.98 | CYP17A1 (0.49) | CYP17A1CYP19A1F7F3SARM1 | |
| SCHEMBL27492286 | 0.85 | CYP19A1 (0.52) | CYP17A1CYP19A1SMN1; SMN2TBXAS1CFTR | |
| SCHEMBL575045 | 0.83 | AKR1C3 (0.57) | CYP17A1CYP19A1SMN1; SMN2TBXAS1CFTR | |
| SCHEMBL22899009 | 0.83 | CYP19A1 (0.51) | CYP17A1CYP19A1SMN1; SMN2TBXAS1CFTR | |
| SCHEMBL6259017 | 0.83 | AKR1C3 (0.57) | CYP17A1CYP19A1SMN1; SMN2TBXAS1CFTR | |
| SCHEMBL306372 | 0.82 | F7 (0.53) | CYP19A1F7F3SARM1SIRT2 | |
| SCHEMBL30338756 | 0.82 | MKNK1 (0.59) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699005-A | 3- (carboxy ethyl) -8- amino -2- oxo -1,3- aza-spiros-[4.5]Decane derivative | 格吕伦塔尔有限公司 | 2018-10-23 | — | — | CN | claimed |
| CN-103687860-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-104744461-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO | 2015-07-01 | — | — | CN | claimed |
| CN-103687860-A | As P2X7Heterocyclic amide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2014-03-26 | — | — | CN | claimed |
| CN-102617567-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO | 2012-08-01 | — | — | CN | claimed |
| EP-2470527-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2012-07-04 | — | — | EP | claimed |
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| CN-1578660-B | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO | 2010-11-24 | — | — | CN | claimed |
| CN-1812786-A | Use of pyrazolopyridines for the treatment of cognitive deficits | EXONHIT THERAPEUTICS SA (FR) | 2006-08-02 | — | — | CN | claimed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | claimed |
| CN-1578660-A | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | CN | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | CYP17A1 1337/4885CYP19A1 3479/4885F7 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.